Compare IDEXX Laboratories, Inc. (IDXX) vs Plby Group Inc (PLBY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IDEXX Laboratories, Inc. vs Plby Group Inc — how do they compare? IDEXX Laboratories, Inc. trades at $557.02 (market cap $44.48B), while Plby Group Inc trades at $1.22 (market cap $139.87M). The key difference: IDEXX Laboratories, Inc. is far larger — about 318× Plby Group Inc's market cap. Which is the better fit depends on your goals.
| IDXX | PLBY | |
|---|---|---|
Market Cap | $44.48B | $139.87M |
Sector | Health | Consumer Cyclical |
52-Week High | $766.68 | $2.71 |
52-Week Low | $520.87 | $1.11 |
Enterprise Value | $45.38B | $287.68M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDXX trades at $563.79, down 0.64% today but maintains strong fundamental momentum with consistent earnings beats and robust profitability. The stock shows bullish technical signals with support at $563 and resistance at $572, while valuation metrics remain elevated. Recent Q1 2026 results exceeded expectations with EPS of $3.47 versus $3.41 estimates, supporting the company's leadership in veterinary diagnostics.
Outlook remains positive given strong analyst support (59% buy ratings) and innovation pipeline, though premium valuations and competitive pressures present risks. Revenue growth trajectory and expanding margins provide fundamental support for continued upside potential in the pet healthcare sector.
PLBY Group trades at $1.21, up 3.42% with a market cap reflecting a P/S ratio of 1.02. The company shows improving fundamentals with five consecutive quarters of positive adjusted EBITDA and narrowing losses, though it remains unprofitable with negative ROE. Technical indicators signal bearish momentum despite neutral oscillators. Recent developments include Russell index inclusion and a strategic share repurchase program.
The outlook remains cautious due to persistent net losses and high debt levels, but operational improvements and brand repositioning offer potential upside. Key risks include execution challenges in licensing growth and competitive pressures in the leisure sector. Analyst consensus is strongly bullish with 75% buy ratings, suggesting confidence in the turnaround strategy.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →About Plby Group Inc
PLBY Group Inc is a pleasure and leisure company. The company's segment includes Licensing, Direct-to-Consumer, and Digital Subscriptions and Content. It generates maximum revenue from the Direct-to-Consumer segment. Direct-to-Consumer operations include consumer products sold through third-party retailers or online direct-to-customer. Geographically, it derives a majority of revenue from the United States.
Read more on PLBY →
